Core Viewpoint - The agreement between Beijing JACOS and AstraZeneca for the development and commercialization of the pan-KRAS inhibitor JAB-23E73 represents a significant collaboration in the oncology sector, with potential financial benefits for Beijing JACOS through upfront and milestone payments [1] Group 1: Agreement Details - Beijing JACOS has entered into a licensing and collaboration agreement with AstraZeneca for the pan-KRAS inhibitor JAB-23E73 [1] - AstraZeneca is granted exclusive rights to research, develop, register, manufacture, and commercialize JAB-23E73 globally, excluding mainland China [1] - In mainland China, the product will be co-developed and co-commercialized by both parties under a governance framework established in the agreement [1] Group 2: Financial Implications - Beijing JACOS is entitled to receive an upfront payment of $100 million from AstraZeneca [1] - The company may receive additional milestone payments totaling up to $1.915 billion upon achieving certain development, regulatory, and commercial milestones [1] - Upon successful commercialization of the product, Beijing JACOS will earn tiered royalties based on the net sales of the licensed product [1]
加科思-B(01167)附属与阿斯利康订立许可与合作协议，以开发及商业化泛KRAS抑制剂JAB-23E73